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Retinal neurodegeneration is an early event in the pathogenesis
of diabetic retinopathy (DR). Somatostatin (SST) is an endoge-
nous neuroprotective peptide that is downregulated in the
diabetic eye. The aim of the study was to test the usefulness of
topical administration of SST in preventing retinal neurodegen-
eration. For this purpose, rats with streptozotocin-induced di-
abetes mellitus (STZ-DM) were treated with either SST eye drops
or vehicle for 15 days. Nondiabetic rats treated with vehicle served
as a control group. Functional abnormalities were assessed by
electroretinography (ERG), and neurodegeneration was assessed
by measuring glial activation and the apoptotic rate. In addition,
proapoptotic (FasL, Bid, and activation of caspase-8 and caspase-
3) and survival signaling pathways (BclxL) were examined. Intra-
retinal concentrations of glutamate and its main transporter
glutamate/aspartate transporter (GLAST) were also determined.
Treatment with SST eye drops prevented ERG abnormalities, glial
activation, apoptosis, and the misbalance between proapoptotic
and survival signaling detected in STZ-DM rats. In addition, SST
eye drops inhibited glutamate accumulation in the retina and
GLAST downregulation induced by diabetes mellitus. We conclude
that topical administration of SST has a potent effect in preventing
retinal neurodegeneration induced by diabetes mellitus. In addi-
tion, our ﬁndings open up a new preventive pharmacological strategy
targeted to early stages of DR. Diabetes 62:2569–2578, 2013
Diabetic retinopathy (DR) has been classicallyconsidered to be a microcirculatory disease ofthe retina. However, there is growing evidenceto suggest that retinal neurodegeneration is an
early event in the pathogenesis of DR that participates in
the microcirculatory abnormalities that occur in DR (1–8).
We have contributed to this ﬁeld by demonstrating that the
main hallmarks of retinal neurodegeneration (apoptosis
and glial activation) are already present in the retinas of
diabetic donors without any microcirculatory abnormali-
ties in ophthalmoscopic examinations performed during
the year before death (9–11).
Glutamate is the major retinal excitatory neurotrans-
mitter for the photoreceptor-bipolar-ganglion cell circuit.
However, elevated glutamate levels in the retina (which
result in excessive stimulation) are implicated in the so-
called “excitotoxicity,” which leads to neurodegeneration
(12). The excitotoxicity of glutamate is the result of over-
activation of ionotropic glutamate receptors, which have
been found to be overexpressed in rats with streptozotocin-
induced diabetes mellitus (STZ-DM) (13,14). Apart from
glutamate, oxidative stress (15), advanced glycation end
product receptor upregulation (16,17), and renin-angiotensin
system activation (18–20) play an essential role in retinal
neurodegeneration induced by diabetes mellitus. Finally,
recent evidence indicates that diabetes mellitus–induced
downregulation of neuroprotective factors synthesized by
the retina is also involved in the neurodegenerative pro-
cess of the diabetic eye (21). On these bases, it is rea-
sonable to hypothesize that therapeutic strategies based
on neuroprotection will be effective in preventing or ar-
resting DR development.
Somatostatin (SST) is one of the most important neu-
roprotective factors synthesized by the retina, retinal pig-
ment epithelium (RPE) being its main source in the human
eye. The human retina produces signiﬁcant amounts of SST,
as deduced by the strikingly high levels reported within the
vitreous ﬂuid (22,23). Besides SST, its receptors (SSTRs)
are also expressed in the retina, with SSTR1 and SSTR2
being the most widely expressed (24). The production of
both SST and its receptors simultaneously suggests a rele-
vant autocrine action in the human retina. SST acts as
a neuromodulator in the retina through multiple pathways,
including intracellular Ca2+ signaling, nitric oxide function,
and glutamate release from the photoreceptors. Apart from
neuroprotection, SST has potent antiangiogenic properties
and regulates various ion/water transport systems (24).
Therefore, SST seems to be essential in preventing both
proliferative DR (PDR) and diabetic macular edema (DME).
In the early stages of DR, there is a downregulation of
SST that is associated with retinal neurodegeneration (9).
In fact, it has recently been reported that intravitreal ad-
ministration of SST and SST analogs protects the retina
from AMPA-induced neurotoxicity (25). In addition, the
lower expression of SST in RPE and neuroretina is asso-
ciated with a dramatic decrease of intavitreal SST levels in
both DME (26) and PDR (22,23). As a result, the physio-
logical role of SST in preventing both ﬂuid accumulation
within the retina and neovascularization could be reduced,
and consequently, the development of DME and PDR
would be favored. For all these reasons, SST replacement
treatment can be considered a new target not only for pre-
venting the neurodegenerative process but also for more
advanced stages of DR such as DME and PDR.
When the early stages of DR are the therapeutic target, it
would be inconceivable to recommend in the clinical
practice an aggressive treatment such as intravitreous in-
jections. On the other hand, the use of eye drops has not
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been considered an appropriate route for the administra-
tion of drugs aimed at preventing or arresting DR because
of the general assumption that they do not reach the
posterior chamber of the eye. However, there is emerging
evidence showing the capacity of a lot of drugs to reach
the retina in pharmacologically effective concentrations, at
least in animal models (27).
On this basis, the aim of the current study was to de-
termine whether topical administration of SST prevents
the retinal neurodegenerative process that occurs in STZ-
induced diabetic rats. In addition, the effects of SST eye
drops on apoptotic/survival signaling pathways and retinal
glutamate levels have been examined. Finally, the possi-
bility that SST acts through preventing glutamate accu-
mulation by upregulating glutamate/aspartate transporter
(GLAST) has also been explored.
RESEARCH DESIGN AND METHODS
A total of 24 male Sprague-Dawley rats were obtained from Charles River
Laboratories (Senneville, Quebec, Canada). A minimum acclimatization period
of 14 days preceded treatment. STZ (60 mg/kg) was administered to 8-week-old
(n = 16) rats by intravenous injection via tail vein on day 22 prior to starting
SST treatment. The remaining eight rats were injected with vehicle and served
as a nondiabetic control group. Animals with blood glucose levels .250 mg/dL
the day after STZ administration were considered diabetic. On day 21, all
animals were weighed and randomly assigned to treatment groups (vehicle or
SST) using a computer-based randomization procedure. Randomization was
performed by stratiﬁcation using body weight as the parameter.
SST or vehicle eye drops were administered directly onto the superior
corneal surface of each eye using a syringe. One drop (20 mL) of SST (1%;
10 mg/mL) or vehicle (20 mL of 0.9% sodium chloride) was administered once
daily for 14 days. On day 15, the animals’ eyes were instilled with a drop of SST
or vehicle ~1 h prior to necropsy. Therefore, the elapsed time between the
onset of diabetes mellitus until necropsy was 16 days.
A dose-response experiment assessing the hallmarks of retinal neuro-
degeneration (apoptosis and glial activation) was performed using SST eye
drops at 10, 2, and 0.5 mg/mL (Table 1).
The animals used in this study were treated in accordance with the Asso-
ciation for Research in Vision and Ophthalmology Statement.
Pharmacokinetic analyses. A pharmacokinetic analysis after a single topical
dose of radiolabeled 125I-somatostatin was performed. For this purpose, seven
rats were anesthetized and placed in a supine position. After they were placed
in the experimental area, 10 mL (2.5 mCi) 125I-somatostatin was applied in each
eye with a micropipette. The animals were killed at 15, 30, and 60 min and 4, 6,
12 and 24 h after the application of the labeled SST solution. After the animals
were killed, the eyes were obtained and gently washed in a volume of 20 mL
physiologic saline. A small incision was performed in the rear portion of the
eye ball, and the eye content was extracted. The vitreous humor, retina, and
choroid-RPE were collected. The sclera was placed in different tubes for in-
dependent measurements. All the samples were weighted and counted in the g
counter in order to obtain the percentage of injected dose for each gram of
tissue. Samples of blood were also obtained.
In addition, absorption of carboxyﬂuorecein-labeled SST (CF-SST) eye
drops through the ocular structures was also evaluated in 8-week-old Sprague-
Dawley rats. For this purpose, three rats were treated with vehicle eye drops in
both eyes. Three rats were treated with the ﬂuorescent label (CF) eye drops.
The eye drops of CF-SST (10 mg/mL; one drop) were administered to the right
eye, and the vehicle was administered to the left eye of three rats. One animal of
each group was killed at 10, 30, and 60 min after the application of the cor-
responding eye drop. The eyes were enucleated, ﬁxed in 4% paraformaldehyde,
submerged in optimum cutting temperature Tissue-teck, frozen in liquid ni-
trogen, and stored at 280°C until microtome sectioned. The whole eyes were
cryosectioned to 50-mm sections, mounted with antifade-mounting medium
with DAPI, and visualized in ﬂuorescent and confocal microscopes (Olympus).
All images were taken with the same settings.
TABLE 1
Experimental design of the dose-efﬁcacy study
Group STZ dose (mg/kg) Treatment
Dose formulation
(mg/mL)
A 0 Vehicle —
B 60 Vehicle —
C 60 SST 0.5
D 60 SST 2
E 60 SST 10
n = 8 in all groups.
FIG. 1. Ocular absorption of 125I-somatostatin expressed as the percentage of applied dose for each gram of tissue (percent dose/g) as a function of
time. Uptake of the radioactivity in the eye content was clearly observed (n = 1 for each time point).
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Ophthalmological examinations. Slit lamp biomicroscopy, indirect oph-
thalmoscopy, and intraocular pressure measurement were performed in all
animals at baseline and at days 7 and 13 posttreatment.
Electroretinography. Electroretinogram evaluations were performed on day
–1 before treatment and on day 14 as follows: the animals were dark adapted
for at least 1 h prior to electroretinography (ERG) recording and then anes-
thetized with isoﬂurane to maintain the anesthesia prior to and during the
procedure. Tropicamide (1%) was applied to each eye prior to the test. A con-
tact lens electrode was placed on the surface of each eye, and a needle elec-
trode was placed cutaneously on the head between the two eyes. A cutaneous
ground electrode was placed near the base of the tail. Carboxymethylcellulose
(1%) drops were applied to the interior surface of the contact lens electrodes
prior to their placement on the eyes. A topical anesthetic (proparacaine, 0.5%)
was applied to the eyes. The amplitude and implicit time of the b-wave after
scotopic ﬂash stimuli were measured. b-wave amplitude and implicit time were
measured as deﬁned by the International Society for Clinical Electrophysiology
of Vision (28).
Histopathology. Eyes were prepared for histopathological examination by
being embedded in parafﬁn wax, sectioned, and stained with hematoxylin-
eosin. For each eye, a total of three sagittal sections (one section through the
optic nerve, one section ~500 mm medially, and another section ~500 mm
laterally from the optic nerve) were evaluated.
Assessment of glial activation. Sections of 7-mm thicknesses were obtained
from the parafﬁn blocks and ﬁxed on highly adherent slides (Vision-
biosystems; Newcastle upon Tyne, U.K.). They were desparafﬁned in xylol;
rehydrated in 100% ethanol, 90% ethanol, and 75% ethanol; and incubated for
10 min in PBS. Unspeciﬁc unions were blocked by incubating the samples for
1 h in PBS 1% BSA and 0.05% Triton X-100. Thereafter, the primary rabbit anti-
human glial ﬁbrillar acidic protein (GFAP) antibody (Sigma, Madrid, Spain)
diluted in the blocking buffer (1:100) was incubated for 36 h at 4°C. After three
washings for 5 min with PBS, the sections were incubated with a secondary
human IgG antibody labeled with Alexa Fluor 568 (Invitrogen, Eugene, OR) for
1 h at room temperature. The labeled sections were washed and mounted with
ﬂuorescent medium containing DAPI for identifying cell nuclei (Vector Lab-
oratories, Burlingame, CA). Positive sections for GFAP were captured in
a confocal microscope (FV1000; Olympus, Hamburg, Germany). Optical sec-
tions were obtained with a 568-nm laser for Alexa Fluor 568 and a 405-nm
laser for the DAPI (image resolution 1,024 3 1,024 pixels). The degree of glial
activation was evaluated by using a score system based on the extent of GFAP
staining (29). This scoring system is as follows: negligible staining (score 0),
Müller cell endfeet region/ganglion cell layer (GCL) only (score 1), Müller cell
endfeet region/GCL plus a few proximal processes (score 2), Müller cell
endfeet plus many processes but not extending to outer nuclear layer (ONL)
(score 3), Müller cell endfeet plus processes throughout with some in the ONL
(score 4), and Müller cell endfeet plus a lot of dark processes from GCL to the
outer margin of ONL (score 5).
Assessment of apoptosis. The In Situ Cell Death Detection kit (Roche
Diagnostics, Mannheim, Germany) was used to evaluate the presence of apo-
ptotic cells. Sections were deparafﬁned in xylol; rehydrated in 100% ethanol,
90% ethanol, and 75% ethanol; and incubated for 10min in PBS. Autoﬂuorescence
FIG. 2. The b-wave amplitude (A) and implicit time (B) under scotopic conditions (0 db) in both eyes at day 21 (□) and at day 14 (■) in the
studied groups. C, control rats; D-sham, diabetic rats treated with vehicle eye drops; D-SST, diabetic rats treated with SST eye drops. Data are
means 6 SD. *P < 0.05.
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was eliminated after incubation with 0.2% potassium permanganate for 20 min
and 1% oxalic acid for 30 s before the TUNEL procedure was started. Positive and
negative controls were processed at the same time. Three confocal images were
recorded (340) corresponding to a surface of 317.13 3 317.13 mm for each
section. Staining with propidium iodide was done to examine nucleus mor-
phology and discard false positives. The total number of nuclei and nuclei
positive for TUNEL were counted with the ImageJ program.
Proapoptotic and survival signaling. Proapoptotic signaling pathways
were investigated by analyzing several proapoptotic molecules (FasL, caspase-
8, total Bid, truncated Bid, and active caspase-3), as well as antiapoptotic
markers (BclxL), by Western blot as previously described (30).
Glutamate quantiﬁcation. Quantiﬁcation of glutamate was performed by
liquid chromatography coupled to mass spectrometry. Chromatographic sep-
aration was performed on an Agilent 1200 series (Waldbronn, Germany) using
an Ascentis Express HILIC column, 503 2.1 mm with 2.7 mm particle size from
Supelco (Belfonte, PA), maintained at 25°C throughout the analysis, a mobile
phase acetonitrile (ACN), and water (50 mmol/L ammonium acetate) with
a ﬂow rate of 0.6 mL/min. The volume injected was 10 mL. The mobile phase
involved a gradient starting at 87% of ACN, which was maintained for 3 min.
Then, from min 3 to 10 the ACN content was decreased to 20% and increased
again to 87% at min 12.5. Glutamate was eluted at 6.5 min. The mass detection
system was an Agilent 6410 Triple Quad (Santa Clara, CA) using positive
electrospray ionization with a gas temperature of 350°C, gas ﬂow rate of 12 L/min,
nebulizer pressure of 45 c, capillary voltage of 3,500 V, fragmentor of 135 V,
and collision energy of 10 V.
GLAST expression
RNA isolation and GLAST mRNA quantiﬁcation. Total RNA was
extracted from retinas with the Rneasy Mini kit with DNAase digestion (Qiagen;
IZASA, Madrid, Spain). One microgram of total RNA was used for reverse
transcription with TaqMan and random primer reagents (Applied Biosystems,
Madrid, Spain). Real-time PCR was performed with the GLAST speciﬁc assay
for exon 3–4 boundary Rn00570130_m1 (Applied Biosystems), and results
were normalized to the expression level of b-actin (Rn00667969_m1) as
a housekeeping gene. Relative quantiﬁcation values were obtained using an
ABI Prism 7000 SDS software (Applied Biosystems).
Immunohistochemistry for GLAST. Sections of 4 mm were deparafﬁned in
xylene and hydrated in a graded ethanol series. Then, sections were antigen
retrieved (sodium citrate 10 mmol/L, pH 6.0) and washed in PBS. Next, sec-
tions were incubated in blocking solution (2% BSA, Tween 0.05% PBS) for 1 h
at room temperature followed by incubation with primary antibody anti-
GLAST (1:200; Abcam, Cambridge, U.K.). After washing, sections were in-
cubated with a ﬂuorescent anti-rabbit Alexa Fluor 488 as a secondary antibody
(Life Technologies, Madrid, Spain) in blocking solution for 1 h, washed, and
mounted in Vectashield (Vector Laboratories). DAPI was used for nuclear
staining. Quantiﬁcation of ﬂuorescence intensity of images was performed as
previously explained for GFAP.
Statistical analysis. Normal distribution of the variables was evaluated using
the Kolmogorov-Smirnov test. Data were expressed either as means6 SD or as
median (range). Comparisons of continuous variables between groups were
performed using the unpaired Student t test or Mann-Whitney U test. For
comparisons within groups (ERG of day 14 vs. ERG of day 21), the paired
Student t test was used. Levels of statistical signiﬁcance were set at P , 0.05.
RESULTS
SST contained in eye drops reached the retina. The
results of pharmacokinetic study are displayed in Fig. 1.
After topical ocular administration of 125I-somatostatin, the
maximum postdose concentration (5% of applied dose per
gram of tissue) was detected at 1 h. However, at 15 min
most of the 125I-somatostatin had already reached the
retina. This rapid absorption argues against the perme-
ation of SST through the cornea. For further exploration of
this issue, a pharmacokinetic study using eye drops con-
taining CF-SST was performed. This study clearly showed
that SST contained in the eye drops reached the retina not
through the cornea but by the trans-scleral route, thus
bypassing the anterior chamber (Supplementary Fig. 1).
FIG. 3. GFAP immunoﬂuorescence. A: Images of representative samples of retina from a control rat (Control), a diabetic rat treated with vehicle
eye drops (D-Sham), and a diabetic rat treated with SST eye drops (D-SST). In diabetic rats, the endfeet of the Müller cells showed abundant GFAP
immunoﬂuorescence (green), and the radial processed stained intensely throughout the inner retina. The topical treatment with SST prevents the
glial activation. Scale bar = 50 mm. B: Quantiﬁcation of glial activation based on extent of GFAP staining. INL, inner nuclear layer.
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Ocular safety of SST treatment. No signiﬁcant differ-
ences in the cornea, pupil size, or intraocular pressure
were observed among the three groups at baseline or
during follow-up.
SST treatment prevents ERG abnormalities. ERG was
performed to assess retinal function. b-wave amplitude
was signiﬁcantly reduced at day 14 in the diabetic group
treated with vehicle (Fig. 2A). By contrast, in the control
group and in the diabetic group treated with SST eye drops
no reduction of b-wave amplitude was observed. b-wave
implicit time increased at day 14 in diabetic rats treated
with vehicle (Fig. 2B). However, in the control group and
in the diabetic group treated with SST eye drops the im-
plicit time did not increase at day 14. Therefore, SST
treatment prevented ERG abnormalities caused by di-
abetes mellitus.
Neurodegeneration was prevented in diabetic rats
treated with SST eye drops
Glial activation. The retinas of nondiabetic control rats
revealed GFAP immunolabeling in cells and their processes
in the inner layer of the retina, especially in the inner lim-
iting membrane, and GCL (GFAP score 0–1) (Fig. 3).
According to their location and morphology, these GFAP-
positive cells were interpreted as being retinal astrocytes.
However, a slight GFAP immunoﬂuorescence in Müller
cells could be detected. In the retina of diabetic rats treated
with placebo, GFAP expression was prominent along the
inner limiting membrane, in Müller cell endfeet, and in
Müller cell radial ﬁbers extending through both the inner
and outer retina (GFAP score 1–3). Diabetic rats treated
with SST eye drops presented signiﬁcantly lower GFAP
score (0–1) than diabetic rats treated with placebo (Fig. 3).
Retinal apoptosis. Representative images of the pres-
ence of apoptotic cells in the retinas of the three experi-
mental groups are shown in Fig. 4A. Two weeks after the
induction of diabetes mellitus with STZ, the whole per-
centage of retinal apoptotic cells, as well as the percentage
of apoptotic cells in retinal layers, was signiﬁcantly higher
in comparison with that observed in retinas from age-
matched nondiabetic controls (Fig. 4B). In all groups, ap-
optosis was highest in the GCL. Diabetic rats treated with
SST eye drops presented a signiﬁcantly lower ratio of ap-
optosis in all retinal layers than diabetic rats treated with
placebo and similar to nondiabetic rats (Fig. 4B).
FIG. 4. A: Representative images of apoptosis in the retina from a control rat, a diabetic rat treated with vehicle eye drops (Diabetes-sham), and
a diabetic rat treated with SST eye drops (Diabetes-SST). B: Percentage of apoptotic cells in the whole retina and in the retinal layers in each
group. Results are expressed as means 6 SD. INL, inner nuclear layer. *P < 0.05 in comparison with control and diabetic SST treatment groups.
Scale bar = 50 mm.
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Dose response effect. The effectiveness of SST eye drops
at concentrations of 2 mg/mL was similar to that of eye
drops at 10 mg/mL concentrations in preventing glial ac-
tivation and apoptosis. However, the effect of 0.5 mg/mL
was signiﬁcantly lower than that obtained using either 2 or
10 mg/mL (Fig. 5).
Proapoptotic and survival molecules. The results of
proapoptotic and survival molecules measured in the ret-
ina of the three rat groups studied are shown in Fig. 6. The
expression of FasL, a proapoptotic component of the
death receptor apoptotic pathway, was signiﬁcantly in-
creased in neuroretinas from diabetic rats compared with
control rats. The interaction of FasL with the death re-
ceptor Fas/CD95 assembles the death-inducing signaling
complex (31). This includes the recruitment of caspase-8.
Activation of caspase-8, monitored by the presence of
its 18-kDa active fragment, was signiﬁcantly increased in
neuroretinas of diabetic rats compared with controls.
These data were reinforced by the detection of elevated
levels of truncated Bid fragment in diabetic samples. As
a result, neuroretina from diabetic rats displayed a sig-
niﬁcant activation of the executer caspase-3, monitored
by the presence of its 17-kDa active fragment. Treatment
with SST eye drops prevented the upregulation of all of
these proapoptotic molecules.
On the other hand, a reduction in BclxL, an anti-
apoptotic member of the Bcl2 family, was found in diabetic
retinas in comparison with control retinas. When treated
FIG. 5. Dose-response effect of SST eye drops on retinal neurodegeneration. A: GFAP immunoﬂuorescence (green) corresponding to represen-
tative samples of retina from a control rat (A1), a diabetic rat treated with vehicle eye drops (A2), and diabetic rats treated with SST eye drops at
doses of 0.5 mg/mL (A3), 2 mg/mL (A4), and 10 mg/mL (A5). B: Quantiﬁcation of glial activation based on extent of GFAP staining corresponding to
all rats (n = 8) of each group. C: Images of apoptosis assessed by TUNEL assay (green) in representative samples of retina from a control rat (C1),
a diabetic rat treated with vehicle eye drops (C2), and diabetic rats treated with SST eye drops at doses of 0.5 mg/mL (C3), 2 mg/mL (C4), and 10
mg/mL (C5). D: Percentage of apoptotic cells in the retinal layers in each group (n = 8). Results are expressed as median (range). Control, control
rats; D-sham, diabetic rats treated with vehicle eye drops; D-SST, diabetic rats treated with SST eye drops; INL, inner nuclear layer. *P < 0.05 in
comparison with diabetic group treated with vehicle. Scale bar = 20 mm.
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with SST eye drops, BclxL expression was greatly im-
proved (Fig. 6).
Topical administration of SST prevents the increase
of glutamate induced by diabetes mellitus. Glutamate
levels (arbitrary units, median [range]) in the diabetic
retinas were higher than in nondiabetic retinas (117 [57–
412] vs. 47 [27–300]; P = 0.012). In diabetic rats treated
with SST eye drops, glutamate concentration (40 [21–127])
was signiﬁcantly decreased in comparison with diabetic
rats treated with vehicle (P = 0.021) and similar to control
rats (P = 0.51).
Upregulation of GLAST expression after SST
treatment. Gene and protein expression of GLAST were
downregulated in retinas of diabetic rats (Fig. 7). In di-
abetic rats treated with SST, this downregulation was
prevented and GLAST protein levels were even increased
in comparison with nondiabetic rats (Fig. 7).
DISCUSSION
In the current study, we provide the ﬁrst evidence that
topical administration of SST prevents retinal neuro-
degeneration in STZ-DM rats. SST eye drops prevented b-
wave abnormalities in the ERG (reduction in amplitude
and increase in implicit time), which are considered sen-
sitive indicators of DR (32). In addition, topical adminis-
tration of SST abrogated the characteristic hallmarks of
neurodegeneration (glial activation and apoptosis) caused
by short-term diabetes mellitus. In this regard, it should be
noted that the degree of glial activation and apoptosis in
diabetic rats treated with SST eye drops was very similar
to that found in nondiabetic rats.
Glial activation is a prominent event in retinal neuro-
degeneration. Retinal astrocytes normally express GFAP,
while Müller cells do not. However, during the course of
diabetes mellitus there is an aberrant expression of GFAP
by Müller cells (33). Because Müller cells produce factors
capable of modulating blood ﬂow, vascular permeability,
and cell survival and because their processes surround all
the blood vessels in the retina, it seems that these cells
play a key role in the pathogenesis of retinal micro-
angiopathy in the diabetic eye (33,34). In this paper, we
have found that SST eye drops were able to signiﬁcantly
prevent glial activation or, in other words, most of the
aberrant expression of GFAP in Müller cells.
Apart from glial activation, apoptosis is the other hall-
mark of retinal neurodegeneration. As previously reported
(35), we found a signiﬁcant rate of apoptosis in retinas
from STZ-induced diabetic rats in comparison with non-
diabetic control rats. In addition, we found a misbalance
between apoptotic and survival signaling pathways. In this
regard, we demonstrated that the activation of the death
receptor pathway, monitored by the elevation in the ex-
pression of FasL and the activation of caspase-8, was
FIG. 6. Apoptotic signaling pathways in the neuroretina of three groups. A: Protein extracts were prepared from neuroretina. Total protein (50 mg)
was used for Western blot analysis with the antibodies against FasL, caspase (casp)-8, Bid, Bim, BclxL, and active caspase-3. a-Tubulin (atub)
antibody was used as a loading control. B: Autoradiograms were quantiﬁed by scanning densitometry. C, control rats; D-Sham, diabetic rats treated
with vehicle eye drops; D-SST, diabetic rats treated with SST eye drops. Results are expressed as arbitrary units of protein expression and are
means 6 SD. *P < 0.05, **P < 0.01, and ***P < 0.005 for diabetic mice treated with the vehicle vs. diabetic mice treated with SST eye drops.
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signiﬁcantly higher in neuroretina from STZ-induced di-
abetic rats than in nondiabetic controls. Importantly, our
data clearly show increased Bid cleavage in the neuro-
retina of diabetic rats. This result suggests that in the di-
abetic neuroretina, the apoptotic signals emerging from
the death receptor pathway are ampliﬁed to additional
activation of the intrinsic apoptotic signaling pathway,
resulting in a stronger activation of the executer caspase-3.
On the other hand, a signiﬁcant downregulation of BclxL
(an antiapoptotic molecule belonging to the Bcl2 family)
was found in diabetic retinas. Notably, topical adminis-
tration of SST was able to prevent all these abnormalities
in proapoptotic/survival signaling.
Apart from the prevention of apoptosis and glial acti-
vation, SST eye drops signiﬁcantly reduced glutamate
retinal levels. Rapid removal or inactivation of glutamate is
necessary to maintain the normal function of the retina
and for avoiding excitotoxicity. Elevated levels of gluta-
mate in the retina have been found in experimental models
of diabetes mellitus (36–38), as well as in the vitreous ﬂuid
FIG. 7. A: GLAST mRNA in control rats (C), diabetic rats treated with vehicle eye drops (D-Sham), and diabetic rats treated with SST eye drops (D-
SST). B: Immunoﬂuorescence of GLAST in representative samples of retina from each group. C: Quantiﬁcation of GLAST immunoﬂuorescence in
the three studied groups. Data are means 6 SD. a.u., arbitrary units; INL, inner nuclear layer. Scale bar = 50 mm.
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of diabetic patients (12,39). The reasons why diabetes
mellitus facilitates extracellular accumulation of glutamate
include 1) an increase of glutamate production by glial
cells due to the loss of the Müller cell–speciﬁc enzyme
glutamine synthetase, which converts glutamate to gluta-
mine (36,37); 2) a reduction in the retinal ability to oxidize
glutamate to a-ketoglutarate (37); 3) the death of neurons
with subsequent release of intracellular contents; and 4)
the impairment of glutamate removal from extracellular
space by the glial cells (12). Regarding this later point, in
the current study we provide evidence that GLAST, the
main glutamate transporter expressed by Müller cells (40),
is signiﬁcantly decreased in STZ-induced diabetic rats.
More importantly, SST eye drops not only completely
prevent GLAST downregulation induced by diabetes mel-
litus but even lead to a signiﬁcant increase in GLAST ex-
pression (mRNA and protein). These ﬁndings can contribute
to our understanding of the underlying mechanisms in-
volved in the retinal reduction of AMPA-induced neuro-
toxicity reported for SST and SST analogs administered
intravitreally (25).
The study of the mechanisms linking neurodegeneration
with early vascular abnormalities is crucial for under-
standing how neuroprotection could also exert beneﬁcial
effects in diabetic microangiopathy. SST may inhibit an-
giogenesis directly through SST receptors present on
endothelial cells (41) and also indirectly through the down-
regulation of vascular endothelial growth factor (VEGF)
(42,43) or by the inhibition of postreceptor signaling events
not only of VEGF but also of other peptide growth factors
such as IGF-1, epidermal growth factor, and platelet-derived
growth factor (44). The potential effects of SST in abro-
gating microvascular impairment are beyond the scope of
the current study, and speciﬁc studies on this issue are ur-
gently needed.
Given the essential role of neurodegeneration in the
pathogenesis of DR, it is reasonable to hypothesize that
therapeutic strategies based on the neuroprotective effects
of SST would be effective in preventing or arresting DR
development. The observation that circulating growth
hormone–IGF-1 production is reduced by SST has been the
basis for proposing systemic administration of SST analogs
for treating DR. However, this concept has not been sup-
ported by clinical intervention trials. The main concerns of
systemic administration of SST are as follows: 1) the
paracrine effects of SST synthesized by the retina involve
SSTR subtypes other than SSTR2, which mediates growth
hormone inhibition and for which octreotide presents high
afﬁnity, and 2) SST analogs do not cross the blood-retinal
barrier and would have access only where there is dis-
ruption of the blood-retinal barrier, thus limiting the
amount of the drug reaching the retinal target tissues. For
these reasons and given that a downregulation of retinal
production of SST occurs in diabetic retina, a replacement
using local administration of the natural peptide seems
a reasonable approach. In this regard, the neuroprotective
effects of topical administration of brimonidine and nerve
growth factor have already been reported in experimental
models (45–47). These ﬁndings open up the possibility of
developing a topical therapy targeting the early stages of
DR in which the use of the only currently established
therapies such as laser photocoagulation or intravitreal
injections of corticosteroids or anti-VEGF agents are in-
appropriately invasive. In addition, topical administration
of drugs limits their action to the eye and minimizes the
associated systemic effects, resulting in higher patient
compliance (48). Therefore, topical therapies could
revolutionize the care of diabetic patients (49). In this
regard, a phase II-III, randomized controlled clinical trial
(EUROCONDOR-278040) to assess the efﬁcacy of SST and
brimonidine administered topically to prevent or arrest DR
has been approved by the European Commission in the
setting of the FP7-HEALTH-2011.
Finally, the route by which SST contained in the eye drops
reaches the retina deserves a brief comment. The pharma-
cokinetic study revealed a rapid absorption of 125I-SST, which
was unexpected for a compound that reached the retina
diffusing through the cornea. The study performed using
CF-SST showed that the absorption of SST eye drops was
mainly by the trans-scleral route.
In summary, we provide ﬁrst evidence that topical ad-
ministration of SST has a potent effect in preventing the
retinal neurodegenerative process that occurs in the early
stages of DR. A preventive effect on the impairment of
survival/apoptotic signaling induced by diabetes mellitus
and a signiﬁcant reduction in glutamate-induced excito-
toxicity are among the mechanisms by which SST exerts
its beneﬁcial actions.
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